UBS

SAN FRANCISCO -- November 12, 2026 -- Thryv Therapeutics closed a $30 million Series B financing led by InClin, Inc., and Chairman and CEO Paul Truex will present the company's SGK1 inhibitor pipeline at the UBS Global Biopharma Conference in London. Existing investors also took part in the round, according to the company.

The fireside chat is scheduled for Tuesday, November 17, 2026, at 3:20 pm GMT (10:20 am ET), on the second day of the November 16-17 conference. Thryv will also hold one-on-one investor meetings. The talk comes before the first efficacy data from the company's lead candidate, THRV-1268, which the company expects in early 2027.

Thryv has completed enrollment in the first efficacy cohort of Wave II, a Phase 2/3 study (NCT07277582) of THRV-1268 in patients with Long QT Syndrome Type 2 and Type 3. Both the Wave II readout and the opening of enrollment in the company's second trial fall in early 2027.

New York – October 08, 2026 -- Gen Z collectors spent more than twice as much on fine art in 2025 and the first half of 2026 than any older generation, according to the Art Basel and UBS Survey of Global Collecting 2026, conducted by Arts Economics with responses from 3,100 high-net-worth individuals across 10 markets including the US, UK, Mainland China, Hong Kong, France, Germany, Japan, Brazil, Australia and Singapore.

Gen Z buyers now dominate the top end of the art market

Nearly half of all collectors who purchased artworks priced above USD 1 million in 2026 were from Gen Z, the survey found. The generation also outspent peers across virtually every collecting category, from fine art to broader collectibles.

New York – September 22, 2026 -- YELL, a payments platform serving consumers and small businesses, has appointed Raphael Blunschi as Chief Executive Officer as the company surpasses 27,000 customers as of September 2026.

Blunschi brings three decades of Swiss banking and asset management experience to YELL's leadership

Blunschi spent more than 30 years across Swiss banking, institutional asset management, and digital assets. He was a founding member of UBS's prime brokerage business and, at RMF/Man Group, built a multi-billion-dollar global managed account platform designed to make hedge fund exposures transparent and institutionally scalable. He then spent 13 years at K2 Advisors, a Franklin Templeton investment company, serving as Chief Administrative Officer, Executive Committee member, and fund board director for eight private funds.